InvestorBrandNetwork (IBN) Content Platform

Golden Triangle Ventures (OTC: GTVH), a multifaceted financial news and publishing company for private and public entities, has begun sales on the Le Pragma CBD product line; GTVH recently acquired Le Pragma, an emerging brand dedicating to providing high-end health, wellness and beauty products to complement an active lifestyle. According to the announcement, Le Pragma’s line of full-spectrum tinctures is live on the company’s website (LePragma.com), and other product lines are being evaluated and tested before adding them to the site. Golden Triangle Ventures has developed a strategic plan to develop Le Pragma into a globally recognized brand.

The plan includes comprehensive data compilation and optimization; a revamped digital presence complete with real-time inventory accountability, order tracking and customer-engagement data; a proactive regulatory stance to develop a fully compliant and professional product offering designed to maintain brand reputation and consumer safety; an inventory management overhaul to improve logistics, reduce shipping times and enhance overall efficiency; in-depth product insights to allow management to make key adjustments to the formulation of the next round of products; and continued affiliate marketing initiatives and outreach as well as a reimagined social media presence. “Launching sales and officially acquiring the Le Pragma CBD product line is an achievement that resulted from years of preparation and an unwavering dedication to complete this goal because of the confidence our entire team has in its potential,” said Golden Triangle Ventures CEO Steffan Dalsgaard in the press release. “I believe this acquisition supports GTV’s overall strategy and will prove to be an extraordinary asset for the company.”

To view the full press release, visit https://ibn.fm/cOrJo

About Golden Triangle Ventures Inc.

Golden Triangle Ventures is a multifaceted consulting company, which operates as the parent business pursuing ventures in the health, entertainment and technology sectors along with others that provide synergistic value to these three core divisions. The company aims to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators that have passion and commitment in these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent the three sectors the company aims to do business in. Golden Triangle Ventures is highly focused on acquiring a well-diversified portfolio of companies under one umbrella, which are all managed and owned by the company. An amazing team of professionals support each division and continue to help Golden Triangle Ventures grow daily. Operating as a publicly traded company enables the ability to provide the support needed to help each subsidiary grow into the businesses that management believes they can and will become. For more information about the company, please visit www.GoldenTriangleInc.com.

NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://ibn.fm/GTVH

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

CISO Global Inc. (NASDAQ: CISO), has unveiled Argo Edge, a powerful tool stack the company has been developing and testing for the past two years. According to the announcement, Argo Edge combines the most sought-after security technologies available with CISO’s proprietary IP and threat feeds to provide a prebuilt, easy-to-implement solution created for use by both government and privately held entities. The new AI-powered security solution, which has been independently valued at $49 million, enhances cybersecurity effectiveness through coordination, integration and automation. The company stated that Argo Edge layers together preconfigured, preintegrated technologies that include cloud firewall as a service (“FaaS”), secure internet gateway, secure authentication, secure service edge (“SSE”) and containerized internet browser sessions for each user. Argo Edge also provides Zero Trust Network Access (“ZTNA”), Cloud Access Security Broker (“CASB”) and Data Loss Protection (“DLP”) capabilities along with overall improved network performance.

“We believe this valuation solidifies CISO Global as a growing leader in the cybersecurity industry, and that the solution’s capabilities validate the company’s ability to deliver on its mission to demystify and accelerate its clients’ journey to cyber resilience,” said CISO Global CEO David Jemmett in the press release. “Unlike most security platforms currently on the market that add complexity and increase the need for additional staff to manage them, Argo Edge leverages automation and preconfigures highly complex security processes.”

To view the full press release, visit https://ibn.fm/Ui8jE

About CISO Global Inc.

CISO Global is an industry leader as a managed cybersecurity and compliance provider. The company is rapidly expanding by acquiring world-class cybersecurity, secured managed services and compliance companies with top-tier talent that utilize the latest technology to create innovative solutions to protect the most demanding businesses and government organizations against continuing and emerging security threats and compliance obligations. For more information about the company, visit www.CISO.inc.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Breezer Ventures (OTC: BRZV) has unveiled an exclusive line of new gin products designed to complement its existing bourbon and ultra-premium vodka. The new product line is offered through Magnum Finest Spirits Inc., BRZV’s wholly owned subsidiary, and was developed in collaboration with Kalifornia Distilleries Inc. based on centuries-old recipes and 300 years of family distilling heritage. The new offering, Magnum 1770 Gin, features hints of juniper and contains a proprietary blend of natural botanicals. Consumers can choose from two packaging options: an innovative and ecoconscious 1.75l Bag in a Box (“BiB”) or stylish square bottles, either 750ml or 1.75l. The company is planning a variety of marketing campaigns along with special events and sponsorships; an official Magnum 1770 VIP Gin Launch Gala Party is also in the works. According to the announcement, Breezer Ventures is in the process of changing its name and ticker symbol to better reflect its focus on Magnum Finest Spirits Inc., a distilled spirits and marketing company with an exceptional line of products. The company will be filing with FINRA for approval to make the change. Magnum expects to release additional news regarding changes to its management team and new product launches in the coming months. “Our Magnum 1770 Gin has been developed over 300 years and recently perfected by our master distiller partners at Kalifornia Distilleries,” said Breezer CEO Freddy Figueroa in the press release.

To view the full press release, visit https://ibn.fm/doOjM

About Breezer Ventures Inc./Magnum Finest Spirits Inc.

Magnum is a distilled spirits and marketing company offering products with a centuries-long history of outstanding quality. What separates Magnum from industry peers is its functionally innovative and environmentally conscious Bag in a Box (“BiB”) packaging and distinctive billboard-style labeling. Never to be associated with discount or bulk, top-shelf Magnum 1770-branded products include an exceptional Bourbon, premium Vodka and an esteemed Gin, as well as trending Flavored Spirits. The company plans to expand on its relationships with the big box wine and liquor stores, warehouse liquor emporiums, traditional liquor stores, VIP and trending restaurants, bars and nightclubs. For more information about this company, please visit www.MagnumFinestSpirits.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has advanced the formulation development for its therapeutic drug, SPC-15. According to the update, formulation development was in accordance with the company’s sponsored research agreement and option with Columbia University, and the liquid nasal formulation will be used in SPC-15’s novel protocol intended for treatment and prevention of anxiety, PTSD and other stress-related disorders. “The progress of our feasibility study investigating dose strengths of SPC-15 is a significant advancement in our development work with this pipeline candidate,” said Eric Weisblum, chief executive officer of Silo Pharma. “Results of the feasibility study will determine our selection of the manufacturing processes, and we are currently in discussions with potential delivery partners. We may also use the feasibility data for upcoming studies related to our SPC-14 therapeutic targeting Alzheimer’s disease.”

To view the full press release, visit https://ibn.fm/RiwDj

About Silo Pharma Inc.

Silo Pharma is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which it believes will be transformative to the well-being of patients and the health care industry. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focusing on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer. The company today announced its appointment of industry veteran George Ng to serve as its chief executive officer and as a board director as of Aug. 8, 2023. Dr. David Young will focus his efforts on the development of the Next Generation Chemotherapy (“NGC”) drugs as president of research and development and as a board member. “We are thrilled to have George assume the leadership of our management team. His extensive managerial experience and proficiency in issues and opportunities afforded small-cap publicly traded biotech companies makes him an ideal fit for our company and will ensure that we continue executing our strategy and create value for our stockholders,” said Processa’s Chairman Justin Yorke. “Late last year, we changed our focus to concentrate on our Next Generation Chemotherapy drugs, with the intention of seeking partnering opportunities for our non-oncology assets. As part of that transition, we have been evaluating how to best position Processa for long-term success and determined now is the right time to transition to our next stage of corporate leadership. Given his oncology and drug development expertise, Dr. Young has decided moving full-time to drug development will allow him to focus on advancing the development of our Next Generation Chemotherapy drugs to subsequent FDA approval.”

To view the full press release, visit https://ibn.fm/xqjIM

About Processa Pharmaceuticals Inc.

Processa is a clinical stage pharmaceutical company focused on developing the Next Generation Chemotherapy drugs to improve the safety and efficacy of cancer treatment. By combining Processa’s novel oncology pipeline with proven cancer-killing active molecules and the Processa Regulatory Science Approach as well as experience in defining Optimal Dosage Regimens for FDA approvals, Processa not only will be providing better therapy options to cancer patients but will also increase the probability of FDA approval for its Next Generation Chemotherapy drugs. Processa’s NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its approach to drug development is based on more than 30 years of drug development expertise to efficiently design and conduct clinical trials that demonstrate a positive benefit/risk relationship. Using its proven Regulatory Science Approach, Processa has experience defining the Optimal Dosage Regimen using the principles of the FDA’s Project Optimus Oncology initiative. The advantages of Processa’s Next Generation Chemotherapy drugs are expected to include fewer patients experiencing side effects that lead to dose discontinuation; more significant cancer response; and a greater number of patients who will benefit from each Next Generation Chemotherapy drug. Currently in its pipeline are three Next Generation Chemotherapy drugs: Next Generation Capecitabine (“PCS6422” and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers), Next Generation Gemcitabine (“PCS3117” to treat pancreatic, lung, ovarian, breast, and other cancers), and Next Generation Irinotecan (“PCS11T” to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers). For more information, visit the company’s website at www.ProcessaPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Standard Lithium (TSX.V: SLI) (NYSE American: SLI) (FRA: S5L) today announced positive results of a preliminary feasibility study (“PFS”) for the company’s 100%-owned South West Arkansas (“SWA”) Project. Among the highlights, the company reported base production of 30,000 tonnes per annum (“tpa”) battery-quality lithium hydroxide monohydrate (“LHM”); upside case of 35,000 tpa. “The robust economics from the South West Arkansas Project PFS showcase its incredible potential,” said Dr. Andy Robinson, president and COO of Standard Lithium. “Our exploration program in the first half of this year yielded significantly improved lithium concentrations and grew the total resource to 1.8 million tonnes of lithium carbonate equivalent. The upgraded resource underpins an operating life of at least 20 years at competitive costs.”

To view the full press release, visit https://ibn.fm/KLnXe

About Standard Lithium Ltd.

Standard Lithium is a leading near-commercial lithium development company with a portfolio of projects in progress. The company’s flagship Lanxess and South West Arkansas projects are located in southern Arkansas near the Louisiana state line. The company is focused on the evaluation and testing of commercial lithium extraction and purification from brine sourced from approximately 180,000 acres of leases across these two projects. The company operates a first-of-a-kind industrial-scale DLE Demonstration Plant at the Lanxess South Plant. The scalable, environmentally friendly process eliminates the use of evaporation ponds, reduces processing time from months to hours and greatly increases the effective recovery of lithium. A feasibility study and front-end engineering study for its first commercial scale lithium extraction plant located at the Lanxess South Plant (Phase 1A of the Lanxess Project) commenced in September 2022. Standard Lithium is targeting completion of a feasibility study for the South West Arkansas Project by the end of 2024. Concurrently, the company is pursuing resource development of other projects in the Smackover Formation in East Texas, as well as approximately 45,000 acres of mineral leases located in the Mojave Desert in San Bernardino County, California. Standard Lithium is jointly listed on the TSX Venture Exchange and the NYSE American under the trading symbol SLI and on the Frankfurt Stock Exchange under the symbol S5L. For more information, please visit the company’s website at www.StandardLithium.com.

NOTE TO INVESTORS: The latest news and updates relating to SLI are available in the company’s newsroom at https://ibn.fm/SLI

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTC: PLTXF), the digital face of the plant-based community operating a one-stop shop for plant-based products, is adding TiNDLE Chicken to its ecommerce fulfillment solutions. The leading plant-based chicken, TiNDLE is made by Singapore-founded food tech start-up TiNDLE Foods, and is the latest in a growing number of brands PlantX has added to its online offerings. The move marks the debut of the full range of TiNDLE Foods being available online for shipment across the United States. TiNDLE chicken offers the distinct aroma, taste and texture of chicken and is made with non-GMO, plant-based ingredients; the product is similar in taste, texture and aroma to chicken.

“We recently completed a widely successful multimonth collaboration with TiNDLE where we transformed our pop-up market in Venice Beach, California, into a TiNDLE destination, including a redesign of the store facade into a custom mural painted by local artist Jules Muck,” said PlantX Life Lorne Rapkin in the press release. “The pop-up featured the new TiNDLE Chicken retail items in a variety of prepared dishes including a Chicken Parm Sandwich, Fried Chicken Sandwich, Chicken & Waffles, Buffalo Chicken Wrap and Sticky Wings. It has been amazing to work with TiNDLE and see firsthand the popularity of their products, and we are excited for this next step of becoming their direct-to-consumer arm to bring their products to household across America.”

To view the full press release, visit https://ibn.fm/aq6eu

About PlantX Life Inc.

PlantX is committed to being the digital face of the plant-based community as well as the one-stop shop for plant-based products. With its fast-growing category verticals, the company offers customers across North America more than 5,000 plant-based products. PlantX also has other brands in the PlantX portfolio, including a juice brand, a coffee company, a plant shop and brick-and-mortar grocery stores. PlantX uses its digital platform to build a community of like-minded consumers and, most importantly, to provide education. PlantX’s digital presence eliminates entry barriers for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life. For more information about this company, please visit www.PlantX.com and www.PlantX.ca.

NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

180 Life Sciences (NASDAQ: ATNF) today announced its entry into an agreement with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and with Prof. Elyad Davidson, of Hadassah Hospital, to perform a clinical pharmacology (“PK”) study of the uptake of cannabidiol (“CBD”) in a formulation that can be delivered as an oral pill. The PK study will seek to determine how much CBD is taken up into the blood of volunteers. “We believe that the new pill formulation has the potential to dramatically improve the availability and absorption of CBD taken orally as a pill, and plan to facilitate clinical studies to test this,” said Prof. Sir Marc Feldmann, executive co-chairman of 180 Life Sciences. “If successful, we believe that this may significantly expand the use of CBD and derivatives and may permit their use in multiple conditions including, most importantly, pain (a huge unmet need where there are few safe drugs), anxiety and … weight management. Recent human studies have demonstrated that CBD can improve post-operative pain and might decrease opioid consumption, an important goal*. This is an exciting prospect and Prof. Domb’s team has a track record in formulating medications for therapeutic use.”

To view the full press release, visit https://ibn.fm/35DoI

About 180 Life Sciences Corp.

180 Life Sciences is a clinical stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy. The company’s current primary focus is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor).

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF

*Talk by Michael J. Alaia, MD, FAAOS concerning the efficacy of an orally absorbed CBD tablet for postoperative pain relief following rotator cuff surgery. Presented at the 2022 American Academy of Orthopaedic Surgeons Annual Meeting.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced positive top-line results from its Phase 3 PALISADE-2 trial. The trial, to evaluate the efficacy, safety and tolerability of fasedienol (“PH94B”) nasal spray in adults diagnosed with social anxiety disorder (“SAD”), met its primary endpoint, with fasedienol demonstrating a statistically significant difference in average SUDS score during a public speaking challenge compared to placebo. The trial also met its secondary endpoint, demonstrating a statistically significant difference in the proportion of clinician-assessed responders between fasedienol and placebo as measured by the CGI-I scale.

“We are thrilled that these compelling top-line results from the Phase 3 PALISADE-2 trial confirm what was seen in the Phase 2 studies in social anxiety disorder and highlight the potential for fasedienol, with its novel and unique proposed mechanism of action, to transform what is possible for more than 25 million people living with social anxiety in the U.S. and millions more affected worldwide,” said Shawn Singh, chief executive officer of Vistagen. “As a new class of medicines, our pherine nasal spray pipeline holds the potential to transform the treatment landscape across numerous therapeutic areas. At the head of that class, fasedienol’s potential, as demonstrated in this Phase 3 trial, sets the stage for the first fundamentally new class of medicine for individuals living with SAD in more than 20 years.”

To view the full press release, visit https://ibn.fm/iKTYL

About VistaGen Therapeutics Inc.

Vistagen is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression and multiple CNS disorders. Vistagen’s pipeline includes six clinical-stage product candidates, including fasedienol (“PH94B”), itruvone (“PH10”), “PH15,” “PH80,” and “PH284,” each an investigational agent belonging to a new class of drugs known as pherines, as well as “AV-101,” which is an oral prodrug antagonist of the N-methyl-D-aspartate receptor (“NMDAR”). Pherines are administered as low microgram dose level nasal sprays and are designed with a novel mechanism of action that activates chemosensory neurons in the nasal cavity and can beneficially impact key neural circuits in the brain without systemic uptake or direct activity on CNS neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety, depression and several other CNS disorders. For more information, visit the company’s website at www.Vistagen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Siyata Mobile (NASDAQ: SYTA, SYTAW), a global vendor of push-to-talk over cellular (“PoC”) devices and cellular signal booster systems, has announced that Tango Tango, a leading provider of critical push-to-talk (“PTT”) communications solutions and an existing reseller of Siyata products, will offer its public safety-focused app on Siyata Mobile’s SD7 Handset along with related SD7 accessories. “We are excited to expand our relationship with Tango Tango and for them to market our industry leading SD7 Handset equipped with their proprietary PTT application,” said Marc Seelenfreund, CEO of Siyata. “Tango Tango primarily serves the first responder, education and health care markets, and its application integrates seamlessly with our SD7 Handset providing us with yet another channel to grow our business and increase our market share.”

To view the full press release, visit https://ibn.fm/2Af9j

About Siyata Mobile Inc.

Siyata Mobile is a B2B global vendor of next-generation push-to-talk over cellular devices, cellular booster systems and video monitoring solutions. Its portfolio of in-vehicle and rugged devices enables first responders and enterprise workers to instantly communicate, over a nationwide cellular network of choice, to increase situational awareness and save lives. Its portfolio of enterprise-grade and consumer cellular booster systems enables first responders and enterprise workers to amplify cellular signals in remote areas, inside structural buildings where signals are weak, and within vehicles for the maximum cellular signal strength possible. For its video monitoring system, Siyata integrates software that it licenses with off-the-shelf hardware providing its customers with an integrated advanced camera system for management and visual monitoring of their fleet vehicles. Siyata’s common shares and previously issued warrants trade on the Nasdaq under the symbols SYTA and SYTAW, respectively. For more information about the company, visit www.SiyataMobile.com and UnidenCellular.com.

NOTE TO INVESTORS: The latest news and updates relating to SYTA are available in the company’s newsroom at https://ibn.fm/SYTA          

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

• FEXD understands the changing dynamics and the growing preference for digital payments
• Through its aggressive yet strategic acquisition approach, FEXD is offering solutions that make it easy to move money across borders
• By prioritizing developing nations and creating systems and infrastructure unique to the needs of customers in these countries, FEXD is addressing the issue of gross unmet mobile needs
• This reflects the company’s commitment to its mission and to creating shareholder value

Fintech Ecosystem Development (NASDAQ: FEXD), a special purpose acquisition company (“SPAC”), is focused on the changing consumer landscape and how digital payments are shaping the way people transact. In response, the company is pushing for the creation and proliferation of much-needed scalable access to systems and infrastructure that facilitate cashless payments, ultimately playing an integral role in advancing a cashless society, both in the U.S. and around the world.

According to Pew Research, it was estimated that, in 2022, two-fifths of Americans used no cash. Additional studies showed that 11% of U.S. adults have stopped using cash, up from 5% five years ago, with the average number of cash payments falling from 26% in 2019 to 20% in…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

Ideanomics (NASDAQ: IDEX), a global company focused on accelerating the commercial adoption of electric vehicles, is reporting on its first quarter 2023 operating results for the period ended March 31, 2023. Highlights of the report included the finalization of a VIA transaction in January; key partnerships announced by subsidiary Energica to advance all-electric solutions for aviation, marine, and off-road uses; the expansion of subsidiary Solectrac’s dealer network and subsidy program for all-electric tractors; the partnership between US Hybrid and Mi-Jack to develop hydrogen-powered rubber tire gantry crane; and the collaboration between US Hybrid and Global Environmental Products to make 18 zero-emission street sweepers for Caltrans. In addition, the report noted that Ideanomics has consolidated all energy and charging solutions under one brand: WAVE Charging. Key numbers from the report include revenues of $10.6 million and gross profit for the quarter totaling ($0.6) million. The company reported that revenue was primarily down “due to a decrease in revenue from Timios the title & escrow services business, and a decrease in revenue from the China-based EV resale business.” The report also noted that, during the first quarter, IDEX began executing on its commitment to shareholders to exit noncore businesses, including the sale of Timios and the shutdown of the company’s Justly financial services business.

To view the full press release, visit https://ibn.fm/zSGp0

About Ideanomics Inc.

Ideanomics is a global group with a simple mission: to accelerate the commercial adoption of electric vehicles. By bringing together vehicles and charging technology with design, implementation and financial services, the company provides the completeness of solutions needed for the commercial world to commit to an EV future. For more information about the company, please visit www.Ideanomics.com.

NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Energy Fuels (NYSE American: UUUU) (TSX: EFR), a leading U.S.-based critical minerals company, reported its financial results for the quarter ended June 30, 2023. Highlights of the report included a “robust” balance sheet showing working capital of $134.36 million, up from $116.97 million in December 2022 ); a net loss of $4.89 million, or $0.03 per share; and an inventory of 766,000 pounds of finished U3O8, 906,000 pounds of finished V2O5, and 37 MT of finished high-purity, partially separated mixed REE carbonate, with an additional 403,000 pounds of U3O8 as raw materials and work-in-progress inventory. The report also noted that, regarding uranium, UUUU sold 80,000 pounds of U3O8 to a major U.S. nuclear utility for $4.34 million; the company anticipates sell an additional 180,000 pounds of U3O8 for an estimated $54–$58 per pound, resulting in an estimated 46%–50% gross margin. Regarding REEs, UUUU produced approximately 99 MT of high-purity, partially separated mixed RE carbonate from monazite during the quarter, and the company also noted in the report that it is continuing to advance its program to evaluate the potential to recover radioisotopes from its process streams for use in emerging targeted alpha therapy cancer therapeutics.

In addition, the company announced that it is hosting a conference call and webcast today at 4 p.m. ET to discuss its second-quarter results as well as the outlook for the remainder of 2023; the call will also provide an overview of UUUU’s uranium, rare earths, vanadium and medical isotopes initiatives. Those interesting in accessing the call can dial 1-888-664-6392, and an operator will connect you to the call. A replay of the call will be available until Aug. 21, 2023; interested parties can dial 1-888-390-0541 or 1-416-764-8677 and enter the replay code 682077#.

“Energy Fuels continued to make excellent progress on all aspects of our core uranium and rare earth businesses during Q2 2023,” said Energy Fuels president and CEO Mark S. Chalmers in the press release. “We completed the sale of 80,000 pounds of uranium to one of our utility customers under one of our long-term contracts. We expect to make another sale of 180,000 pounds of uranium under another long-term contract later this year. . . . Energy Fuels also remains on schedule to complete ‘phase 1’ of our rare earth project at the White Mesa Mill in Utah, which involves modifications and enhancements to the mill’s existing SX building that are expected to have the capacity to produce approximately 800–1,000 metric tons of separated NdPr oxide per annum. . . .Later this year, we expect to begin pilot work on ‘heavy’ rare earth separation, including the production of separated dysprosium and terbium oxides. At the same time, we continue to move our Bahia Rare Earth Project in Brazil forward toward production and to secure additional sources of monazite supply to process at the Mill for rare earth production. . . . To say Energy Fuels continues to make rapid and extraordinary progress on creating a ‘critical mineral hub’ in Utah to help the United States ‘reshore’ critical mineral capabilities required for many advanced clean energy, defense and other technologies is truly an understatement.”

To view the webcast, visit https://ibn.fm/pjZqI

To view the full press release, visit https://ibn.fm/joBHQ

About Energy Fuels Inc.

Energy Fuels is a leading U.S.-based critical minerals company. As the leading producer of uranium in the United States, Energy Fuels mines uranium and produces natural uranium concentrates that are sold to major nuclear utilities for the production of carbon-free nuclear energy. Energy Fuels recently began production of advanced rare earth element (“REE”) materials, including mixed REE carbonate, and plans to produce commercial quantities of separated REE oxides in the future. Energy Fuels also produces vanadium from certain of its projects, as market conditions warrant, and is evaluating the recovery of radionuclides needed for emerging cancer treatments. Its corporate offices are in Lakewood, Colorado, and substantially all its assets and employees are in the United States. Energy Fuels holds two of America’s key uranium production centers: the White Mesa Mill in Utah and the Nichols Ranch in-situ recovery (“ISR”) project in Wyoming. The White Mesa Mill is the only conventional uranium mill operating in the country today, has a licensed capacity of more than 8 million pounds of U3O8per year, has the ability to produce vanadium when market conditions warrant, as well as REE products, from various uranium-bearing ores. The Nichols Ranch ISR project is on standby and has a licensed capacity of 2 million pounds of U3O8per year. The company recently acquired the Bahia Project in Brazil, which is believed to have significant quantities of titanium (ilmenite and rutile), zirconium (zircon) and REE (monazite) minerals. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101-compliant uranium resource portfolios in the United States and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Fintech Ecosystem Development Corp. (NASDAQ: FEXD), a company formed to develop a global financial technology ecosystem, continues to develop a diverse portfolio of FinTech-related products and services to consumers and businesses in the United States, South Asia, East Asia, Africa, Europe, and Latin America. “FinTech innovations affect various dimensions of financial services, including domestic payments, credit, remittances, savings, insurance, and investment management,” reads a recent article. “[FEXD’s] products are intended to help consumers buy products and services from anywhere, make payments across borders, remit money to recipients in other countries, and send money to people in remote locations who may not have access to traditional banking services. Thus, given the role of money transfers in boosting recipients’ purchasing power, FinTech Ecosystem Development aims to empower underserved populations in various regions worldwide.”

To view the full article, visit https://ibn.fm/bxVSf

About Fintech Ecosystem Development Corp.

Fintech Ecosystem Development is a special purpose acquisition company formed for the purpose of effecting one or more business combinations with an intent to focus on the financial technology sector. The company is sponsored by Revofast LLC and the management team led by CEO, president and founder Dr. Saiful Khandaker and a group of experienced fintech business and technology innovators. For more information about the company, please visit www.FintechEcosys.com.

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Environmental Solutions Group Holdings Limited (“ESA Holdings”) is a sustainable waste solutions provider with a mission to recycle industrial waste into circular products using innovative technologies and renewable energy through its operating entity in Singapore, Environmental Solutions (Asia) Pte. Ltd. (“ESA”). The company, together with Genesis Unicorn Capital Corp. (NASDAQ: GENQ), a special purpose acquisition company, have announced the successful closing of their business combination, which was approved at a special meeting of Genesis stockholders on July 26, 2023, and closed on Aug. 2, 2023. The combined company, ESGL Holdings Limited (NASDAQ: ESGL, ESGLW),will be led by ESA’s existing management team. “The closing of the transaction and our listing on Nasdaq is an important milestone and an incredibly proud moment for the entire ESGL team,” said Quek Leng Chuang, founder, CEO and chairman of the board of ESGL. “ESGL is uniquely positioned to harness the momentum of Singapore’s sustainability drive and carbon reduction objectives. With our commitment to innovative technologies and renewable energy, we effectively convert industrial waste into circular products, aligning with our core mission. This strategic transaction bolsters our access to capital, empowering us to seize multiple avenues for growth. As we advance our mission of circularity and sustainability, we enable our partners to reduce their environmental impact, contributing to creating a more resilient planet.”

To view the full press release, visit https://ibn.fm/63SXW

About Environmental Solutions Group Holdings Limited

Environmental Solutions Group Holdings Limited (“ESA Holdings”) is a holding company incorporated as an exempted company under the laws of the Cayman Islands. ESA Holdings conducted all its operations through its operating entity incorporated in Singapore, Environmental Solutions (Asia) Pte. Ltd. (“ESA”). ESA is a waste management, treatment and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical and electroplating companies. ESA currently has two revenue streams, including 1) services income, which is primarily comprised of the fees it charges its customers for its waste collection and disposal services, which fees are similar to those charged by ESA’s competitors, and 2) the sales and trading of ESA’s circular products made and processed from the recycled waste collected from its customers with respect to its waste collection and disposal services, which ESA believes makes it a unique and environmentally friendly offering in the marketplace. On Nov. 30, 2022, ESA Holdings and Genesis Unicorn Capital Corp. (NASDAQ: GENQ) entered into a definitive agreement for a business combination. Upon the closing of the business combination on Aug. 2, 2023, the combined company is named ESGL Holdings Limited and its new ticker symbol will be ESGL commencing with trading on Aug. 4, 2023. For more information, please visit https://esgl.asia for company filings.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

The BuildClub, the AI-driven on-demand marketplace for building materials, today announced the achievement of a significant milestone in its equity crowdfunding campaign with the successful raise of over $400,000 on the StartEngine platform. Powered by cutting-edge AI technology, the platform aggregates the buying process, scanning over 15 million products daily from 225 suppliers across 14 cities. This advanced approach provides customers with access to the most competitive prices and an extensive range of high-quality building materials. “We are ecstatic to have reached this impressive milestone in our journey,” said Stephen Forte, founder and CEO of The BuildClub. “The overwhelming support from our investor community showcases the confidence they have in our vision to disrupt the construction industry and bring unparalleled convenience to contractors and homeowners alike.”

To view the full press release, visit https://ibn.fm/Mo8Zw

About The BuildClub

The BuildClub, an on-demand marketplace for building materials, is revolutionizing the construction and home improvement industry. Powered by AI with an emphasis on convenience and efficiency, The BuildClub’s on-demand platform is a one-stop shop, offering 2-hour job site delivery for over 240,000 items. Visit The BuildClub website or download the app directly from the app stores.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, has closed its previously announced overnight marketed public offering. In connection with the offering, the company issued an aggregate of 24,264,706 units of the company, each at a price of US$0.34, for aggregate gross proceeds of US$8,250,000. Cybin intends to use the net proceeds for the progression of its CYB003 and CYB004 programs and for general corporate and working capital purposes. Cantor Fitzgerald & Co. acted as sole book-running manager and A.G.P./Alliance Global Partners acted as lead manager for the offering.

To view the full press release, visit https://ibn.fm/yn2Cm

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental health care is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

• Forbes reports that “2023 travel trends show no slowdown”
• SHRG’s MyTravelVentures offers members full access to exclusive deals across the travel industry
• The company just wrapped up an exclusive premium resort getaway to Cancun, Mexico

As travel spending continues to trend upward, Sharing Services Global (OTCQB: SHRG) wholly owned subsidiary, MyTravelVentures, celebrated a milestone: the company just completed its first-ever Venture Trip at the Sensira Resort and Spa in Cancun, Mexico (https://ibn.fm/61KkX). MyTravelVentures is a subscription-based travel company that offers access to wholesale travel savings, and the company is looking to strengthen its position as the travel space grows.

According to a recent report from the U.S. Travel Association, total travel spending In May improved to 1.4% above May 2022 levels and was up 5.5% year-to-date through…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

Forrester (NASDAQ: FORR) has announced the full conference agenda for Data Strategy & Insights 2023. The event is slated to take place September 13–14, 2023, both in Austin, Texas, and digitally. As generative AI rapidly permeates every business domain, the event will showcase the technology’s potential while providing insight on navigating unique challenges, such as trustworthiness, regulatory and governance issues, and the risk of harmful content creation. At the event, Forrester analysts will share the latest research, best practices and client stories about how to innovate with AI and analytics in a responsible and secure manner. Engaging topics will include modern data architectures and emerging technologies in data management, how data governance increases collaboration, alignment and trust across organizations, and why data sharing, security and understanding yield better insights-driven decision-making. “As innovation in generative AI and data analytics accelerates, technology, data and analytics leaders face tough decisions over how these technologies and insights will deliver the most impactful outcomes for their business,” said Srividya Sridharan, event research chair and VP, group research director at Forrester. “Data Strategy & Insights will offer best practices and guidance for leaders to both grow insights-driven teams that fuel customer obsession and achieve organizational success with AI, data and analytics safely and compliantly.”

To view the full press release, visit https://ibn.fm/LPlrP

About Forrester

Forrester is one of the most influential research and advisory firms in the world. It helps leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at the center of their leadership, strategy and operations. Its unique insights are grounded in annual surveys of more than 700,000 consumers, business and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave(TM) evaluations; 100 million real-time feedback votes; and the shared wisdom of its clients. To learn more, visit Forrester.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

DarioHealth (NASDAQ: DRIO), a leader in the global digital health market, today announced that it will release its financial results for the second quarter ended June 30, 2023, before market opens on Thursday, Aug. 10, 2023. Also on Aug. 10, the company will host a conference call and webcast at 8:30 a.m. Eastern Time, led by Dario’s CEO Erez Raphael and President Rick Anderson. Interested parties should visit https://ibn.fm/r2HU9 to register for and access the webcast and join the call by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or visiting the Call me(TM) link for telephone access to the event. Participants are asked to dial in approximately 10 minutes prior to the start of the call. A replay will be available as detailed in the announcement.

To view the full press release, visit https://ibn.fm/n4g2f

About DarioHealth Corp.

DarioHealth is a leading digital health company, revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Its platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. Dario’s user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to health care. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do. Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO  

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

McEwen Mining (NYSE: MUX) (TSX: MUX), a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina, and McEwen Mining Inc., which is partially owned by MUX, have appointed a new exploration director. The companies announced that Darren King will be taking over the role. King brings more than three decades of international experience in all stages of copper and gold exploration. Prior to joining McEwen, King was VP of exploration at INV Metals and mine exploration manager for South America at Barrick Gold Corporation. He has played key roles in advancing regional exploration properties; ensuring compliance with safety, social, and environmental standards; developing and implementing exploration programs; and creating innovative geological models that lead to significant discoveries. “We are delighted to have Darren join McEwen Copper,” said McEwen Cooper VP and general manager Michael Meding in the press release. “With his more than 27 years of working in Argentina and experience in exploring the High Andes, we believe that his expertise and track record of success will play a key role in further enhancing Los Azules, which is already ranked as a top 10 copper project worldwide with significant growth potential.”

To view the full press release, visit https://ibn.fm/R7fbP

About McEwen Mining Inc.

McEwen Mining is a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina. In addition, it owns approximately 52% of McEwen Copper, which owns the large, advanced-stage Los Azules copper project in Argentina. The company’s goal is to improve the productivity and life of its assets with the objective of increasing its share price and providing a yield. McEwen Mining chair and chief owner Rob McEwen has a personal investment in the company of $220 million; his annual salary is $1. To learn more about the company, visit www.McEwenMining.com.

NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at https://ibn.fm/MUX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development will report its financial results next week. The company announced that it will release the information for the second quarter ended June 30, 2023, after markets close on Aug. 10, 2023. In addition, Predictive Oncology has scheduled a corporate update conference call and live audio webcast for that same day; that event will begin at 5:30 p.m. ET. To access the call, participants may dial toll free 877-407-3982 or 201-493-6780 for international calls, then use conference ID 13739784. The webcast will be available for replay on the company’s website.

To view the webcast, visit https://ibn.fm/ClyDe

To view the full press release, visit https://ibn.fm/2R9m6

About Predictive Oncology Inc.

Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence (“AI”) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. With the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based, drug-discovery solutions, further complemented by its wholly owned CLIA lab and GMP facilities. For more information about the company, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

RYVYL (NASDAQ: RVYL) leverages the security of the blockchain and USD-pegged stablecoin technology with near-real-time attestation capabilities to conduct payment transactions. The company today announced that, on July 31, 2023, it closed the first of two exchange transactions with an existing noteholder under the terms of an agreement dated July 25, 2023. According to the update, 6,000 shares of Series A Convertible Preferred Stock were issued to the noteholder in exchange for $4,297,000 of the outstanding principal balance of the note and $1,703,000 of accrued interest. As recently announced, under the terms of the agreement, the company and the noteholder agreed to exchange, in two separate transactions, an aggregate of $22.703 million of the outstanding principal and interest under an outstanding convertible note, held by the noteholder, for 15,000 shares of RYVYL’s Series A Preferred Convertible Stock. The remaining $16,703,000 in principal, not closed on, under the terms of the agreement, is to be exchanged for 9,000 shares of Series A Convertible Preferred Stock at an additional closing, subject to the satisfaction of certain conditions, including obtaining stockholder approval for the issuance of all shares of common stock underlying the Series A Convertible Preferred Stock, in accordance with Nasdaq rules and regulations.

To view the full press release, visit https://ibn.fm/8ejOK

About RYVYL Inc.

RYVYL was born from a passion for empowering a new way to conduct business-to-business, consumer-to-business and peer-to-peer payment transactions around the globe. By leveraging unique blockchain security and USD-pegged stablecoin technology with near real-time attestation capabilities, RYVYL is reinventing the future of financial transactions using its coyni(R) stablecoin platform as a transactional foundation. Since its founding as GreenBox POS in 2017 in San Diego, RYVYL has developed applications enabling an end-to-end suite of turnkey financial products with enhanced security and data privacy, world-class identity theft protection, and rapid speed to settlement. As a result, the platform can log immense volumes of immutable transactional records at the speed of the internet for first-tier partners, merchants and consumers around the globe. For more information, visit www.RYVYL.com.

NOTE TO INVESTORS: The latest news and updates relating to RVYL are available in the company’s newsroom at https://ibn.fm/RVYL

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

180 Life Sciences (NASDAQ: ATNF) is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain. The company today announced that it has submitted a request to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (“MHRA”) for a follow-up scientific advice meeting where the company will seek guidance on a plan to obtain Conditional Marketing Authorization (“CMA”) for the use of adalimumab in the treatment of early stage Dupuytren’s disease. The meeting is anticipated to take place in the late third quarter, with written responses anticipated to be received prior to year-end 2023. According to the company’s regulatory consultants, an additional clinical trial (phase 3) may be required to obtain CMA approval, and such a trial has been designed. ATNF’s regulatory consultants believe obtaining of a CMA may be possible due to the long safety history of anti-tumor necrosis factor (“TNF”) therapies, conditional on a successful phase 3 trial, which, upon patient enrollment, the CMA may be granted prior to completion and based on the company’s commitment to complete the phase 3 trial.

To view the full press release, visit https://ibn.fm/tEnly

About 180 Life Sciences Corp.

180 Life Sciences is a clinical stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy. The company’s current primary focus is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor).

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is spotlighted on the latest InvestmentPitch Media release. The media release discusses FSD Pharma’s recently executed definitive agreement that grants exclusive rights to Celly Nutrition for recreational applications of its alcohol misuse technology and the launch of UNBUZZD(TM), a revolutionary rapid alcohol detoxification drink. According to the agreement, Celly Nu will pay FSD a license fee by issuing 100,000,000 shares and a 7% royalty on gross revenue if a product is commercialized while FSD will retain all rights to medical and pharmaceutical applications under its umbrella to further develop the franchise. A new great-tasting functional beverage, UNBUZZD has been by FSD Pharma to provide relief from inebriation and accelerating alcohol metabolism.

The beverage contains a proprietary formulation of natural ingredients, vitamins and minerals and assists with liver and brain function to reduce the effects of alcohol consumption. The formulation was curated through scientific research to expediate recovery from inebriation and to accelerate ethanol metabolism in your body, potentially eliminating any performance concerns, the announcement noted. “Zeeshan Saeed, President and Executive Co-Chairman, stated: “This is a major milestone for our company,” said FSD Pharma president and executive cochair Zeeshan Saeed in the press release. “It is a huge step in taking our science to a commercialized product. We have the best and brightest people leading this product commercialization and roll-out, as they were instrumental in the breakthrough, significant ramp up and success with Celsius.”

To view the full media release, visit https://ibn.fm/IGUBN

To view the full press release, visit https://ibn.fm/seXFv

About FSD Pharma Inc.

FSD Pharma Inc. is a biotechnology company with two candidates in different stages of development. Lucid Psychss Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-MS and UNBUZZD(TM). Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle. For more information about the company, please visit www.FSDPharma.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a clinical-stage biotechnology company dedicated to developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs. The company today announced its appointment of Australia-based Jason Carroll as the company’s new chief executive officer, effective Oct. 1, 2023. Carroll brings a wealth of experience as a highly regarded life sciences executive, with an impressive 32-year career in the industry. “Jason’s broad knowledge of the healthcare space, combined with his multi-disciplinary approach and strategic vision, make him an ideal fit to lead our company forward. His experiences navigating complex healthcare systems in both developed and emerging markets will undoubtedly further our immediate and long-term goals,” said Gage Jull, Tryp Therapeutics’ chairman. “Dr. Jim Gilligan’s invaluable stewardship as Tryp’s interim CEO during our search has set the stage for the next phase of Tryp’s development. We extend our sincere gratitude to Jim for his service and are excited for him to return to his core role as chief scientific officer. With this exceptionally strong executive team in place, we believe Tryp is poised for significant success over the coming months and years.”

To view the full press release, visit https://ibn.fm/BcFr5

About Tryp Therapeutics Inc.

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) that alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The company has initiated a phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, where an interim analysis showed an average reduction in binge eating episodes of greater than 80%. The company is also planning for phase 2a clinical trials with the University of Michigan for the treatment of fibromyalgia and with Mass General Hospital for the treatment of  abdominal pain related to irritable bowel syndrome. Each of the studies are utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate efficacy in these indications. Where a preliminary clinical benefit is demonstrated, subsequent studies are expected to utilize TRP-8803 (IV-infused psilocin), which has the potential to further improve efficacy, safety and patient experience. For more information about the company, please visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

FOR IMMEDIATE RELEASE

[Scottsdale, AZ] — GolfLync, the leading social networking platform for golfers, is thrilled to announce the launch of the GolfLync Pebble Beach Sweepstakes. This exciting sweepstakes gives golf enthusiasts a chance to win a dream golf trip to the iconic Pebble Beach Resorts, renowned as the No. 1 Golf Resort in America.

Pebble Beach Resorts, nestled on California’s breathtaking Monterey Peninsula, offers an unparalleled golfing experience. With its three Top 50 public courses, including the world-famous Pebble Beach Golf Links, golf at Pebble Beach Resorts is an unforgettable journey. From the stunning coastal views at…

Read More>>

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

Lottery.com (NASDAQ: LTRY, LTRYW) today announced two significant milestones in its journey towards revenue growth and stability. According to the announcement, the company has successfully regained compliance with another Nasdaq listing requirement and secured a credit facility with United Capital Investments London Ltd. (“UCIL”). The initial loan of $1 million, along with an additional credit facility of up to $49 million, will enable Lottery.com to bolster its financial position and pursue strategic opportunities. “Reaching an agreement with UCIL and regaining compliance with another Nasdaq listing rule are strong indications that the company is making progress on its recovery plan,” reads the statement issued by independent non-executive directors of the company. “The board felt strongly that it was time to find an alternative lender to Woodford Eurasia Assets Ltd., as the withholding of their funding was hindering many of our operational and revenue plans. With the financial backing from UCIL, we expect to quickly move forward with our operational goals and to capitalize on the promising opportunities that lie ahead.”

To view the full press release, visit https://ibn.fm/kryID

About Lottery.com

Lottery.com is a leading technology company that is transforming how, where and when lotteries are played. Its engaging mobile and online platforms enable players and commercial partners located throughout the United States and other countries to remotely purchase safe and legally sanctioned lottery games. Lottery participants look to the company’s website, Lottery.com, for compelling, real-time results on over 800 lottery games from over 40 countries. In all that it does, Lottery.com’s mission remains the same: an uncompromising passion to innovate, grow a new demographic of enthusiasts, deliver responsible and trusted solutions, and promote community and philanthropic initiatives. For more information, visit www.Lottery.com.

NOTE TO INVESTORS: The latest news and updates relating to LTRY are available in the company’s newsroom at https://ibn.fm/LTRY

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

More than 2,000 financial analysts, business owners, investors, financial institutions, regulators, and business pioneers, are invited to attend the FinovateFall to be held in the Marriott Marquis Times Square, New York, September 11-13, 2023. The transformative event promises to be a catalyst for industry trends, innovative ideas, and robust connections. It will feature the top financial leaders and visionaries who will share insights into the latest financial technology solutions. 50% of the attendees will be from banks and other financial institutions.

As the world’s leading fintech conference, FinovateFall is committed to driving collaboration among the top players in the fintech ecosystem. The event will provide a unique opportunity to advance financial innovation and provide a comprehensive understanding of the cutting-edge advancements that are…

Read More>>

To learn more, please visit https://ibn.fm/sLe8Y.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER), the nation’s largest independent alkaline water company and the Clean Beverage(R) company, is expanding its production capacity by working with a new co-packing partner: A1 Beverages (OTC: AWON). TA1 Beverages owns and operates a bottling and labeling facility in Halcott, New York; the company recently completed a new packaging and bottling production line and has plans to further expand capacity in 2024. The announcement noted that the collaboration is important to The Alkaline Water Company for the continued growth of its Alkaline88(R) brand in the northeastern region of the United States as well as support the company’s pathway to profitability by reducing costs associated with outbound shipping. “Over the past two years, we have strategically grown a network of copackers to improve efficiencies, meet demand and reduce shipping costs,” said The Alkaline Water Company president and CEO Frank Chessman in the press release. “A1 Beverages will be an important producer of Alkaline88, and their addition as a partner in New York further strengthens our capacity, capabilities, and cost efficiencies in the Northeast.”

To view the full press release, visit https://ibn.fm/QeLB1

About The Alkaline Water Company

The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with ecofriendly aluminum packaging options. With its innovative, state-of-the-art, proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked Clean Beverage label. To learn more about the company, please visit www.Alkaline88.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

DarioHealth (NASDAQ: DRIO), a leader in the global digital health market, is offering a new program designed to provide support for individuals using GLP-1s and other anti-obesity drugs. The program is designed to support changes in behavior and help users leverage the full potential of medications while improving overall health; the program also has potential to deliver valuable insights to Dario’s partners. GLP-1s weight-loss medications are approved for use by adults with certain related chronic conditions. Dario’s new whole-health program is designed to help people reach their weight-loss goals. The company’s proven combination of innovative technologies and human support focuses on changing underlying health behaviors. According to the announcement, members using a GLP-1 or other anti-obesity medications who enroll in Dario’s cardiometabolic solution will receive a highly personalized experience optimizing digital coaching and professional human support to improve overall health. In addition, members will be able to access DRIO’s new Medication Cabinet, which is a digital tool designed to assist members in tracking medication adherence. “The standard of care for obesity is evolving, and we believe Dario’s proven ability to sustainably change behaviors will best help our members and partners realize the full potential of these anti-obesity medications: long-term weight loss and better overall health,” said Dario president Rick Anderson in the press release. “Our wealth of data insights today guides member engagement alongside medical weight loss interventions, and this new program adds a new dimension to the level of insights and guidance we can provide our partners on this emerging priority.”

To view the full press release, visit https://ibn.fm/1rA4h

About DarioHealth Corp.

DarioHealth Corp. is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multichronic condition digital therapeutics platform. Dario’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. The company’s user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results, and making the right thing to do the easy thing to do. Dario provides its highly user-rated solutions globally to health plans and other payors, self-insured employers and providers of care as well as directly to consumers. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting the price and size of the public offering it announced earlier this week. According to the company, 24,264,706 units of the company will be sold at a price of $0.34 per unit, resulting in an estimated $8.25 million in gross proceeds. The announcement noted that one unit will include one common share in the capital of the company and one common share purchase warrant, with the warrants being exercisable to acquire one common share at $0.40 per common share for 60 months. Closing of the offering is expected approximately Aug. 4, 2023, with the final offering completion being subject to market and other customary conditions and approvals. The company noted that it expects to use the funds from the offering for the progression of CYBN’s CYB003 and CYB004 programs, as well as for general corporate and working capital purposes.

In addition, Cybin announced that dosing in cohort 6 of its phase 2 study evaluating CYB003 has begun. The cohort is the final cohort of the CYB003 study; CYB003 is an investigational deuterated analog of psilocybin for the potential treatment of major depressive disorder (“MDD”). The announcement noted that thus far CYB003 has demonstrated a robust psychedelic response and a favorable safety and tolerability profile at doses up to 12 mg; dosage in the other cohorts ranged from 1 mg to 12 mg. The company anticipates completion of dosing in Q3 2023, with phase 2 topline efficacy data expected later in the third or fourth quarter. “As we begin the final dose escalation cohort in our phase 2 study, we are moving closer than ever towards our goal of determining an optimal dose for CYB003 and assessing CYB003’s potential as a safe and effective therapeutic for people in need of improved treatment options for major depressive disorder,” said Cybin CEO Doug Drysdale in the press release. “We are very pleased with the excellent safety data for CYB003 in participants to date and look forward to reporting phase 2 efficacy topline data later this year and preparing for data submission to the FDA for pivotal studies.”

To view the full press releases, visit https://ibn.fm/2Lydm and https://ibn.fm/ow0mA

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder; the company also has a research pipeline of investigational psychedelic-based compounds. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has announced the passing of one of its directors. The company released a statement “with great sadness” announcing that David Tousley, who also served as the chair of the company’s audit committee, had passed away. “Dave was a highly experienced director who provided the board with consistent, sage advice,” the company stated in the press release. “His input was always well-reasoned and practical on issues brought to the board. He worked tirelessly on behalf of TRYP and was always available for discussions on many detailed matters. We will miss both his commentary and humor. We are deeply saddened by the loss of a dear colleague and friend, and we offer our sincerest condolences to his family.”

To view the full release, visit https://ibn.fm/w8FBG

About Tryp Therapeutics Inc.

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) that alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The company has initiated a phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, where an interim analysis showed an average reduction in binge eating episodes of greater than 80%. The company is also planning for phase 2a clinical trials with the University of Michigan for the treatment of fibromyalgia and with Mass General Hospital for the treatment of abdominal pain related to irritable bowel syndrome. Each of the studies are utilizing TRP-8802 (synthetic oral psilocybin) to demonstrate efficacy in these indications. Where a preliminary clinical benefit is demonstrated, subsequent studies are expected to utilize TRP-8803 (IV-infused psilocin), which has the potential to further improve efficacy, safety and patient experience. For more information about the company, please visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Flora Growth (NASDAQ: FLGC), a consumer-packaged goods leader serving all 50 states and 13 countries with 15,000+ points of distribution around the world and a pharmaceutical distributor in 28 countries, is partnering with the world-renowned Hulk Hogan. According to the announcement, Flora Growth and Hogan, a WWE superstar, have entered into an exclusive worldwide agreement. The agreement outlines Flora Growth’s plans to produce and sell Hogan’s comprehensive consumer products portfolio globally through its Just Brands platform; anticipated products include Hulk Hogan’s hemp-derived pre-rolls, topicals, flower, edibles, CBD, HHC, Delta 8 and Kratom. “Our exclusive partnership with Flora allows us to deliver Hulk Hogan’s vision of a premier brand to the consumer,” said Hulk Hogan, the face of iconic trademarks including Hulk Hogan, Hulkamania, Hollywood Hulk Hogan and the Hulkster.

“I am excited to stand behind my brand with Flora. I used to tell my Hulkamaniacs to say their prayers, take their vitamins, and they will never go wrong. Well, let me tell you something, brother. Flora is the ideal partner to make my CBD-infused vitamins.” According to Carma HoldCo., which creates iconic global brands through licensing and was involved in the negotiations, the exclusive agreement has an initial three-year term with one-year renewal periods; the company noted that the anticipated initial 24-month, top-line sales target is $20 million, with Flora expected to pay a royalty and a license fee. “Flora is thrilled to be selected as the exclusive producer for Hulk Hogan products,” said Flora Growth CEO Clifford Starke in the press release. “Our award-winning products and Hulk Hogan’s status as an icon and American hero will make us the ultimate championship tag team.”

To view the full press release, visit https://ibn.fm/ATREV

About Flora Growth Corp.

Flora Growth is a consumer-packaged goods leader serving all 50 states with 15,000-plus points of distribution around the world and is a pharmaceutical distributor in 28 countries. In the United States, Flora’s lifestyle business has established a robust presence across all 50 states, providing the company with a solid foundation. Furthermore, the company possesses substantial potential for international expansion. Based in Germany, Flora Growth has successfully developed a strong distribution network delivering lifestyle and wellness products to 28 countries. For more information about the company, please visit www.FloraGrowth.com.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

• FEXD is working to develop a global financial technology ecosystem comprising a network of mobile money platforms, technologies, applications, products, and services
• The company aims to use emerging technologies like blockchain, web 3.0, AI, and the metaverse to reduce costs and accelerate the processing of money transfers, loans, and other lifestyle services
• Blockchain is disrupting financial institutions in new ways, creating an entirely new market and an avenue to bank the unbanked
• It offers benefits such as speed, security, accessibility, transparency, and cost reductions
• FEXD hopes to leverage emerging technologies like blockchain to ease the process of moving money across borders

When Satoshi Nakamoto, a mysterious figure whose identity remains unknown more than a decade later, launched Bitcoin, a digital currency built on top of a peer-to-peer network that recorded transactions by “hashing them into an ongoing chain of hash-based proof-of-work” that could not be changed “without redoing the proof-of-work” (https://ibn.fm/9rYlI), they may only have had an inkling of what they had set in motion.

But as revolutionary as the idea of a digital currency backed by a proof-of-work chain, later renamed the blockchain, appears presently, it did not immediately catch on, much like most technologies. While Satoshi published their proof-of-work white paper in 2008 and launched Bitcoin at the beginning of the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]